Steven Eisenberg, MD
Cardiovascular Disease · Atlanta, GANPI 1902849565
Payments from drug & device makers
Across 490 payments — averaging $49.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- Amgen$5K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$1K
- plus $5K from 27 others
What the payments were for
- Consulting fees$5202%
- Speaking & faculty fees$12,48551%
- Travel & lodging$1,2965%
- Food & beverage$9,89641%
- Education$1981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 63 | $5,834 |
| Amgen | 60 | $5,477 |
| Boston Scientific | 16 | $2,927 |
| Edwards Lifesciences | 22 | $1,867 |
| E.r. Squibb & Sons, L.L.C. | 21 | $1,752 |
| Johnson & Johnson | 59 | $1,203 |
| Novartis | 46 | $950 |
| AstraZeneca | 34 | $624 |
| Pfizer | 27 | $588 |
| Amarin Pharma, Inc. | 24 | $450 |
| Merck | 18 | $341 |
| Atricure, Inc. | 3 | $311 |
| Astellas Pharma US Inc | 8 | $291 |
| Esperion Therapeutics, Inc. | 15 | $284 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $274 |
| Heartflow, Inc. | 8 | $184 |
| Sanofi-aventis U.S. LLC | 8 | $160 |
| Regeneron Healthcare Solutions, Inc. | 6 | $141 |
| Kowa Pharmaceuticals America, Inc. | 11 | $129 |
| Abiomed | 3 | $119 |
| Vital Connect, Inc | 4 | $114 |
| Abbott | 4 | $87 |
| Novo Nordisk | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $50 |
| Bardy Diagnostics, Inc. | 3 | $29 |
| Chiesi USA, Inc. | 1 | $26 |
| Exelixis Inc. | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| Medicure Pharma Inc. | 1 | $14 |
| Medicomp Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,395 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 755 | $922,550 |
| Repatha SureclickEvolocumab | 260 | $342,977 |
| XareltoRivaroxaban | 201 | $242,980 |
| Praluent PenAlirocumab | 76 | $85,648 |
| JardianceEmpagliflozin | 43 | $70,234 |
| EntrestoSacubitril/Valsartan | 22 | $32,703 |
| MultaqDronedarone Hcl | 13 | $20,471 |
| Ezetimibe | 567 | $16,352 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 32 | $11,600 |
| FarxigaDapagliflozin Propanediol | 12 | $10,453 |
| Rosuvastatin Calcium | 674 | $7,648 |
| Dofetilide | 21 | $6,683 |
| Atorvastatin Calcium | 643 | $5,303 |
| ClopidogrelClopidogrel Bisulfate | 415 | $4,748 |
| Metoprolol Succinate | 323 | $4,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $588 | $922,550755 claims |
| Johnson & JohnsonXarelto | $1,203 | $242,980201 claims |
| Boehringer IngelheimJardiance | $5,834 | $70,23443 claims |
| NovartisEntresto | $950 | $32,70322 claims |
| Sanofi-aventis U.S. LLCMultaq | $160 | $20,47113 claims |
| AstraZenecaFarxiga | $624 | $10,45312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Bobby KhanAtlanta$1.7M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
- Joseph MillerAtlanta$771K
- Mani VannanAtlanta$716K
- Gautam KumarAtlanta$639K
- Melvin EcholsAtlanta$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.